Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer.

doi:10.1158/1078-0432.CCR-17-0291

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Sept 2017

Janku Filip, Zhang Shile, Waters Jill, Liu Li, Huang Helen J, Subbiah Vivek, Hong David S, Karp Daniel D, Fu Siqing, Cai Xuyu, Ramzanali Nishma M, Madwani Kiran, Cabrilo Goran, Andrews Debra L, Zhao Yue, Javle Milind, Kopetz E Scott, Luthra Rajyalakshmi, Kim Hyunsung J, Gnerre Sante, Satya Ravi Vijaya, Chuang Han-Yu, Kruglyak Kristina M, Toung Jonathan, Zhao Chen, Shen Richard, Heymach John V, Meric-Bernstam Funda, Mills Gordon B, Fan Jian-Bing, Salathia Neeraj S

Abstract excerpt

Purpose: Tumor-derived cell-free DNA (cfDNA) in plasma can be used for molecular testing and provide an attractive alternative to tumor tissue. Commonly used PCR-based technologies can test for limited number of alterations at the time. Therefore, novel ultrasensitive technologies capable of testing for a broad spectrum of molecular alterations are needed to further personalized cancer therapy.Experimental...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to Genetic Testing

Share to High-Throughput Nucleotide Sequencing

Share to Neoplasms

Share to Prognosis

Share to Reproducibility of Results

Share to Sensitivity and Specificity

Source

Open in PubMed Open full text

Identifiers

PMID: 28536309
DOI: 10.1158/1078-0432.CCR-17-0291
PMCID: PMC5600825

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer.PMID 28536309Read ↗

The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.Semantic proximity Read ↗

Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome ConsortiumSemantic proximity Read ↗

Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers.Semantic proximity Read ↗

Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients.Semantic proximity Read ↗

Personalized Cancer Monitoring Assay for the Detection of ctDNA in Patients with Solid Tumors.Semantic proximity Read ↗

Detection of somatic mutations in cell-free DNA in plasma and correlation with overall survival in patients with solid tumorsSemantic proximity Read ↗

Routine Molecular Screening of Patients with Advanced Non-SmallCell Lung Cancer in Circulating Cell-Free DNA at Diagnosis and During Progression Using OncoBEAMTM EGFR V2 and NGS Technologies.Semantic proximity Read ↗

Analytical validation of a next generation sequencing liquid biopsy assay for high sensitivity broad molecular profiling.Semantic proximity Read ↗

Cell-free DNA (cfDNA): Clinical Significance and Utility in Cancer Shaped By Emerging TechnologiesSemantic proximity Read ↗

Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNASemantic proximity Read ↗

Analytical and clinical validation of an amplicon-based next generation sequencing assay for ultrasensitive detection of circulating tumor DNASemantic proximity Read ↗

Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNASemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.